Badania kliniczne: przegląd

Phase I tests five to ten candidate drugs on a small group of healthy individuals or patients to evaluate toxicity, side effects, pharmacokinetics, and pharmacodynamics. This initial phase determines whether the drug is safe enough to proceed to larger patient populations and establishes baseline tolerability and safety data for advancement.

Phase II expands testing to 100-300 patients to monitor drug efficacy and dosage regulation. Phase III involves double-blind, randomized trials with thousands of patients across multiple centers to comprehensively compare the new drug against existing alternatives or placebos, making it more costly and time-consuming than phase II.

Phase IV, or postmarketing surveillance, monitors long-term and rare adverse effects in large patient populations after FDA approval. This ongoing phase ensures drug safety continues to be tracked throughout its use in the general population and identifies effects that may not appear in earlier trial phases.

After phase III success, a New Drug Application is submitted to the FDA with a detailed dossier of preclinical and clinical data. The FDA reviews the submission, and approval can take a year or longer, with approximately two-thirds of submissions receiving marketing approval for commercial distribution.

The complete drug development process, including clinical trials, spans 7 to 12 years. This extended timeline reflects the rigorous testing required across preclinical development overview phases, multiple clinical trial phases, and regulatory review before a drug reaches the market for patient use.

Clinical trials must adhere to Good Clinical Practice guidelines, ensuring meticulous patient group selection, data collection, statistical analysis, and documentation. Phase III trials increasingly incorporate pharmacoeconomic analysis to assess both clinical and economic benefits of new drugs before regulatory submission and approval.

Successful candidates from phase I demonstrate acceptable safety profiles and provide data on pharmacokinetics and pharmacodynamics. Only drugs showing sufficient tolerability and lack of prohibitive toxicity advance to phase II testing in larger patient groups to evaluate therapeutic efficacy and optimal dosage.